Steps for updating an mAb's availability and priority

The availability of a monoclonal antibody (mAb) changes when the mAb is 1) entering next phase of clinical trials; 2) being granted permission or EUA by US FDA; 3) being granted permission by a major country government (CN, EU, or UK). Here listed steps need to be taken for updating an mAb's availability status in DRDB:

1. Update following columns of antibodies.csv:

   Column	Value
   availability	"EUA" if granted EUA by FDA "Approved" if approved by FDA "XX-Approved" if approved by a major country government (e.g. CN-Approved, EU-Approved, etc.) Phase 1/2/3 for in clinical trials
   priority	ranking order: FDA approved (priority<50) EUA approved (priority<50) non-US approved (priority<50) phase 3 (priority between 50 to 500) phase 2 (priority between 50 to 500) phase 1 (priority between 50 to 500)
   visibility	TRUE for "Approved", "EUA" and "XX-Approved". Case by case decision required for "Phase 1/2/3".

2. Update the mAb description. For example: hivdb/chiro-cms@28f3b41.